AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
Log in

NASDAQ:JAGXJaguar Health Stock Price, Forecast & News

$0.45
+0.01 (+2.59 %)
(As of 06/3/2020 12:20 PM ET)
Add
Compare
Today's Range
$0.44
Now: $0.45
$0.47
50-Day Range
$0.41
MA: $0.48
$0.64
52-Week Range
$0.35
Now: $0.45
$17.00
Volume68,778 shs
Average Volume4.08 million shs
Market Capitalization$26.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Read More
Jaguar Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$0.16 per share

Profitability

Net Income$-38,540,000.00
Net Margins-755.26%

Miscellaneous

Employees40
Market Cap$26.55 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.

Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

How has Jaguar Health's stock been impacted by COVID-19 (Coronavirus)?

Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, JAGX shares have increased by 0.2% and is now trading at $0.4510. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Jaguar Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jaguar Health.

When is Jaguar Health's next earnings date?

Jaguar Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Jaguar Health.

How were Jaguar Health's earnings last quarter?

Jaguar Health Inc (NASDAQ:JAGX) announced its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.56) EPS for the quarter. The biotechnology company earned $0.87 million during the quarter. Jaguar Health had a negative net margin of 755.26% and a negative return on equity of 538.90%. View Jaguar Health's earnings history.

What price target have analysts set for JAGX?

2 brokerages have issued twelve-month price targets for Jaguar Health's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Jaguar Health's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 786.9% from the stock's current price. View analysts' price targets for Jaguar Health.

Has Jaguar Health been receiving favorable news coverage?

News headlines about JAGX stock have trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news aboutJaguar Health.

Who are some of Jaguar Health's key competitors?

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biopharmx (BPMX), Conatus Pharmaceuticals (CNAT), Cara Therapeutics (CARA), Precipio (PRPO), Neovasc (NVCN), PTC Therapeutics (PTCT), Achieve Life Sciences (ACHV), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and Novavax (NVAX).

Who are Jaguar Health's key executives?

Jaguar Health's management team includes the following people:
  • Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
  • Ms. Karen S. Wright, CFO & Treasurer (Age 63)
  • Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
  • Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
  • Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel

When did Jaguar Health IPO?

(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.16%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View institutional ownership trends for Jaguar Health.

Which major investors are buying Jaguar Health stock?

JAGX stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel, and Lisa A Conte. View insider buying and selling activity for Jaguar Health.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.45.

How big of a company is Jaguar Health?

Jaguar Health has a market capitalization of $26.52 million and generates $5.78 million in revenue each year. The biotechnology company earns $-38,540,000.00 in net income (profit) each year or ($6.89) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.

What is Jaguar Health's official website?

The official website for Jaguar Health is www.jaguaranimalhealth.com.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.